Eli Lilly’s Foundayo Reduces Sleep Apnea Severity in Late-Stage Trial

According to CNBC, Eli Lilly said its obesity pill Foundayo significantly reduced obstructive sleep apnea severity in a late-stage trial and that it plans to seek U.S. approval for the treatment by the end of the year. Among patients not using positive airway pressure (PAP) therapy, the apnea-hypopnea index fell by an average of 21.1 events per hour at 52 weeks, versus 4.8 for placebo. For patients who continued PAP therapy, the average reduction was 18.3 events per hour, compared with 5.5 for placebo. Foundayo also reduced patients’ weight by roughly 11% across both study groups at 52 weeks.